BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET.
Related Questions
How does the clinical data for CTX‑8371 presented today affect the company's development timeline and potential market launch?
What were the key financial metrics for Q2 2025 (revenue, net loss, cash on hand) and how do they compare to prior quarters?
What preclinical milestones were reported for CTX‑10726, and what is the expected timeline to move into clinical trials?
Did the company address any potential regulatory challenges or FDA interactions related to the tovecimig program?
Are there any disclosed partnerships, licensing deals, or collaborations that could impact future revenue streams?
How might the upcoming data releases influence the valuation of CMPX relative to its oncology peers?
What is the anticipated impact of these updates on the stock price in the short term (e.g., intraday volatility) and long term (e.g., growth trajectory)?
What are the interim results or any early efficacy/safety signals from the tovecimig Phase 2/3 study?
What is the competitive landscape for the indications targeted by tovecimig, CTX‑8371, and CTX‑10726, and how does Compass Therapeutics differentiate its assets?
Did Compass Therapeutics provide any updated guidance for cash runway or future capital requirements?